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Aims We evaluated the influence of concomitant mineralocorticoid receptor antagonists (MRAs) on the safety and neu-
rohumoral effects of a direct renin inhibitor in the ALiskiren Observation of Heart Failure Treatment (ALOFT) study.
Methods
and results
Patients with stable New York Heart Association class II– IV heart failure (HF), plasma B-type natriuretic peptide
(BNP) concentration .100 pg/mL, and treated with an angiotensin-converting enzyme inhibitor (or angiotensin
receptor blocker) and b-blocker were randomized to once-daily, double-blind treatment with aliskiren 150 mg or
placebo, added to optimal HF therapy, for 12 weeks. Safety, tolerability, and effects of aliskiren on neurohumoral
biomarkers were assessed in patients who received (MRA+) and did not receive (MRA2) MRA treatment at base-
line. Of the 302 randomized patients, 101 were receiving MRA treatment (aliskiren, n ¼ 52; placebo, n ¼ 49). Miner-
alocorticoid receptor antagonist status did not affect the ability of aliskiren 150 mg, added to standard HF therapy, to
lower BNP, N-terminal proBNP, plasma renin activity, and urinary aldosterone. For example, the end-of-study to
baseline ratio of geometric mean for BNP was: MRA+ group: aliskiren 0.68 [95% confidence interval (CI) 0.47,
0.98], placebo 0.85 (0.58, 1.24); MRA2 group: aliskiren 0.62 (0.45, 0.84), placebo 0.85 (0.63, 1.15), interaction
P ¼ 0.720. The incidence of pre-specified adverse events (renal dysfunction, symptomatic hypotension, and hyperka-
laemia) was low, and there were no significant differences between aliskiren and placebo in either MRA subgroup.
Conclusion Aliskiren 150 mg added to standard HF therapy was well tolerated over 12 weeks and provided beneficial changes in
neurohumoral biomarkers regardless of concomitant MRA treatment.
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Introduction
The ALiskiren Observation of Heart Failure Treatment (ALOFT)
study was a randomized, placebo-controlled study in 302 patients
with symptomatic heart failure (HF). The study assessed the safety
and neurohumoral effects of adding the direct renin inhibitor (DRI)
aliskiren 150 mg once daily to standard therapy including an
angiotensin-converting enzyme (ACE) inhibitor [or angiotensin
receptor blocker (ARB), but not both] and a b-blocker.1 ALOFT
showed that aliskiren was effective in reducing levels of plasma
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B-type natriuretic peptide (BNP) and plasma N-terminal prohor-
mone BNP (NT-proBNP), and was generally well tolerated over
a 12-week period. Approximately one-third of patients in
ALOFT were receiving a mineralocorticoid receptor antagonist
(MRA) at baseline before being randomized to receive aliskiren
or placebo, and could therefore have received combination treat-
ment with three agents acting on the renin–angiotensin–aldoster-
one system (RAAS), i.e. an ACE inhibitor or ARB, MRA, and DRI
(or even four agents if the renin-suppressing action of b-blockers
is considered). The use of MRAs is likely to increase as a result
of the findings of the recently reported Eplerenone in Mild
Patients Hospitalization And SurvIval Study in Heart Failure
(EMPHASIS-HF) study.2,3 In view of this and the concern about
the safety of using multiple RAAS inhibitors,4,5 a post-hoc subgroup
analysis of ALOFT was undertaken to provide further insight into
the potential efficacy and safety of adding aliskiren to the
regimen of patients already receiving multiple RAAS inhibitors.
This analysis is particularly relevant in the light of a major
ongoing mortality and morbidity trial, Aliskiren Trial to Minimize
OutcomeS in Patients with HEart failuRE (ATMOSPHERE) in
which aliskiren is being added to conventional therapy, including,
if the investigator chooses, an MRA.6
Methods
This was a post-hoc subgroup analysis of data from the ALOFT trial, a
multicentre, randomized, double-blind, placebo-controlled study in
patients with symptomatic HF that has been described in detail else-
where.1 This subgroup analysis evaluated patients according to
whether they had or had not received an MRA as part of their standard
HF therapy at baseline (MRA+ and MRA2 subgroups, respectively).
The study was performed in accordance with the International Confer-
ence on Harmonisation Guideline for Good Clinical Practice and the
Declaration of Helsinki, and approved by the local and central ethical
review boards, and all patients provided written informed consent.
Patients
Men and women aged ≥18 years with stable HF (New York Heart
Association classes II– IV), a current or past diagnosis of hypertension,
plasma BNP concentration .100 pg/mL (.28.9 pmol/L), and receiv-
ing a stable dose of an ACE inhibitor (or ARB) and a b-blocker
(unless contraindicated or not tolerated) were eligible for inclusion.
Patients receiving an ACE inhibitor in combination with an ARB
were excluded from the study. Other key exclusion criteria included:
HF related to obstructive valve disease or hypertrophic, restrictive,
or infective cardiomyopathy; pregnancy; lung disease; systolic blood
pressure ,90 mmHg; and myocardial infarction, cerebrovascular acci-
dent, transient ischaemic attack, or coronary revascularization within
6 months of initiating screening.
Study design and assessments
Following a 2-week, single-blind, placebo run-in period to establish eli-
gibility, patients were randomized equally to receive once-daily treat-
ment with either aliskiren 150 mg or placebo for 12 weeks, in
addition to their current HF therapy. Randomization was stratified
according to left ventricular ejection fraction (LVEF) at baseline
(LVEF .40% and ≤40%), and patients were evaluated at baseline
and 12 weeks after randomization.
The primary objective of this study was to evaluate the safety and
tolerability of aliskiren, specifically the incidence of the pre-defined
adverse events of renal dysfunction [elevation of serum creatinine
levels to .3.0 mg/dL (.265 mmol/L) or other adverse events
related to renal dysfunction], hyperkalaemia (serum potassium levels
.5.5 mmol/L or other adverse events related to hyperkalaemia) and
symptomatic hypotension.
Efficacy endpoints included changes from baseline to the end of the
study in levels of plasma NT-proBNP and other neurohumoral bio-
markers, such as plasma BNP, plasma renin activity (PRA), plasma
renin concentration (PRC) and urinary aldosterone, and mean sitting
systolic and diastolic blood pressure (msSBP and msDBP). Echocardio-
grams were performed at the screening and Week 12 assessments, and
were used to evaluate changes in cardiac size and left ventricular
function.
Plasma renin activity was measured by means of radioimmunoassay
of generated angiotensin I (DiaSorin kit; DiaSorin, Stillwater, MN,
USA), of which the lower limit of quantification (LLOQ) was 0.2 ng/
mL/h. Plasma renin concentration was measured by immunoradiome-
try using a solid-phase sandwich assay (Renin III Generation, CIS Bio
International, Gif-sur-Yvette, France; LLOQ 1.0 pg/mL), as described
initially by Ménard and co-workers and subsequently modified by
Nussberger and colleagues. Plasma BNP concentration was measured
using a two-site dual-monoclonal immunochemiluminescent assay
(ADVIA Centaur BNP assay, Siemens Centaur XP, Malvern, PA,
USA, Diagnostics Division). Plasma NT-proBNP concentration was
measured using a chemiluminescent immunometric assay (Roche Diag-
nostics NT-proBNP Assay on ELECSYS 2010, Indianapolis, IN, USA).
Total urinary aldosterone level was measured by radioimmunoassay
(Siemens, Deerfield, IL, USA) following acidification with 3.2 N HCl
and incubation for 24 h at room temperature in the dark.
All biomarkers were measured at Clinical Research Laboratories,
Medinet in Breda, the Netherlands, or Lenexa, KS, USA. The coeffi-
cients of variation for the assays were as follows: PRA—17.1% at
0.20 ng/mL/h to 5.3% at 8.83 ng/mL/h; PRC—9.24% at 4.49 pg/mL
to 7.22% at 43.29 pg/mL; BNP—5.85% at 39.2 pg/mL to 3.95% at
1535 pg/mL; NT-proBNP—3.6% at 131 pg/mL to 3.1% at 4259 pg/
mL; urine aldosterone—7.2% at 15.8 mg/L to 5.5% at 78.5 mg/L.
Statistical analysis
Baseline parameters were compared for differences between treat-
ment groups within the MRA+ and MRA2 subgroups, using the
t-test statistic for continuous characteristics and the x2 statistic
(Fisher’s exact test when any particular expected count was ≤5)
for categorical characteristics. Between-treatment comparisons
using least-squares means were performed for aliskiren vs. placebo
in the overall population and within each of the MRA+ and
MRA2 subgroups. In order to perform the subgroup analysis,
changes from baseline to endpoint (Week 12) were analysed
using an analysis of covariance (ANCOVA) model with treatment,
region, LVEF (.40 or ≤40%) and subgroup as factors, baseline as
a covariate and treatment by subgroup as an interaction. A log-
transformation was applied before analysis of the neurohumoral par-
ameters (NT-proBNP, BNP, PRA, PRC, and urinary aldosterone).
Treatment comparisons for the primary safety parameters, and
the incidence of adverse events and laboratory abnormalities
within each subgroup were analysed using Fisher’s exact test or
the x2 test. All statistical analyses were performed using SAS
version 8.2 (or higher).
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Results
Following the 2-week placebo run-in period, 302 patients were
randomized to once-daily treatment for 12 weeks with aliskiren
150 mg (n ¼ 156) or placebo (n ¼ 146), in addition to standard
therapy for HF (ACE inhibitor or ARB, plus b-blocker). In total,
277 patients (91.7%) completed the double-blind treatment
phase. A total of 101 patients (aliskiren, n ¼ 52; placebo, n ¼ 49)
were receiving MRA treatment at baseline as part of their back-
ground HF therapy.
Baseline patient characteristics
Patient characteristics were generally well matched between the alis-
kiren and placebo treatment arms within each of the MRA2 and
MRA+ subgroups (Table 1). Patients in the MRA+ subgroup
tended to be younger than patients in the MRA2 subgroup (mean
age of 65 vs. 69 years, respectively) and a greater proportion of
them (31 vs. 22%, respectively) were obese [body mass index
(BMI) ≥30 kg/m2]. There was a lower proportion of men (70 vs.
82%) and a lower proportion of patients with ischaemic heart
disease (48 vs. 58%) in the MRA+ subgroup than in the MRA2 sub-
group, respectively. The proportion of patients receiving an ACE
inhibitor was slightly higher in the MRA+ subgroup than in the
MRA2 subgroup (90 vs. 81%, respectively). The most commonly
used ACE inhibitors were ramipril (n ¼ 88), enalapril
(n ¼ 60), lisinopril (n ¼ 33), and perindopril (n ¼ 28). The median
daily doses in the aliskiren and placebo groups, respectively, were
ramipril (5 vs. 5 mg), enalapril (20 vs. 10 mg), lisinopril (20 vs.
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Table 1 Baseline demographic, clinical, and disease characteristics (intent-to-treat population)














Age, year 68.4+10.2 67.4+10.6 70.2+9.8 68.4+10.4 64.9 + 10.2 65.3 + 10.8
Male, n (%) 111 (76.0) 125 (80.1) 81 (83.5) 84 (80.8) 30 (61.2) 41 (78.8)
Caucasian, n (%) 144 (98.6) 150 (96.2) 97 (100) 101 (97.1) 47 (95.9) 49 (94.2)
Clinical characteristics
eGFR, mL/min/1.73 m2 67.8 + 19.1 70.0 + 21.3 68.4 + 20.7 69.2 + 20.5 66.4 + 15.8 71.7 + 22.9





4.9 + 5.3 4.1 + 3.9 4.7 + 5.7 3.9 + 3.7 5.1 + 4.6 4.3 + 4.3
Aetiology, n (%)
Ischaemic 79 (54.1) 86 (55.1) 56 (57.7) 61 (58.7) 23 (46.9) 25 (48.1)
Idiopathic
cardiomyopathy
29 (19.9) 36 (23.1) 18 (18.6) 25 (24.0) 11 (22.4) 11 (21.2)
Hypertensive 25 (17.1) 25 (16.0) 18 (18.6) 15 (14.4) 7 (14.3) 10 (19.2)
Other 13 (8.9) 9 (5.8) 5 (5.2) 3 (2.9) 8 (16.3) 6 (11.5)
LVEF ≤40%, n (%)a 122 (92.4) 132 (95.0) 77 (79.4) 90 (86.5) 45 (91.8) 42 (80.8)
NYHA class, n (%)
I 1 (0.7) 0 1 (1.0) 0 0 0
II 87 (59.6) 98 (62.8) 58 (59.8) 69 (66.3) 29 (59.2) 29 (55.8)
III 58 (39.7) 56 (35.9) 38 (39.2) 34 (32.7) 20 (40.8) 22 (42.3)
IV 0 2 (1.3) 0 1 (1.0) 0 1 (1.9)
Duration of
hypertension, years
12.3 + 9.6 11.4 + 8.7 12.8 + 10.2 10.5 + 8.6 11.2 + 8.4 13.3 + 8.7
Diabetes, n (%) 49 (33.6) 57 (36.5) 36 (37.1) 38 (36.5) 13 (26.5) 19 (36.5)
Concomitant medication
ACE inhibitor, n (%) 123 (84.2) 130 (83.3) 77 (79.4) 85 (81.7) 46 (93.9) 45 (86.5)
ARB, n (%) 21 (14.4) 25 (16.0) 18 (18.6) 19 (18.3) 3 (6.1) 6 (11.5)
b-blocker, n (%) 138 (94.5) 147 (94.2) 92 (94.8) 96 (92.3) 46 (93.9) 51 (98.1)
All values are mean+ SD unless otherwise stated.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction;
MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SD, standard deviation.
aAs measured by core echocardiography laboratory.
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12.5 mg), and perindopril (4 vs. 2 mg). In the aliskiren group at base-
line, 8 patients were treated with potassium canrenoate 25 mg daily;
2 with eplerenone 25 mg, and 1 with 50 mg daily; 5 with spironolac-
tone 12.5 mg, 23 with 25 mg, 1 with 37.5 mg, 11 with 50 mg, and 2
with 100 mg daily. In the placebo group, 4 patients were treated
with potassium canrenoate 25 mg, 6 with 50 mg, and 1 with
125 mg daily; none with eplerenone and 2 with spironolactone
12.5 mg, 26 with 25 mg, 9 with 50 mg, and 1 with 100 mg daily.
Baseline neurohumoral and echocardiographic parameters
were also well matched between aliskiren and placebo treat-
ment arms within each MRA subgroup (Table 2). Patients in
the MRA+ subgroup had higher geometric mean baseline
PRA (aliskiren 2.8, placebo 3.8 ng/mL/h) and PRC (aliskiren
35.7, placebo 46.5 ng/L) than those in the MRA2 subgroup
(PRA: aliskiren 1.4, placebo 1.8 ng/mL/h; PRC: aliskiren 21.0,
placebo 25.6 ng/L).
Changes in neurohumoral parameters
In the overall population, aliskiren 150 mg added to standard HF
therapy significantly reduced geometric mean BNP (36%),
NT-proBNP (27%), PRA (82%), and urinary aldosterone (19%)
levels compared with placebo, and significantly increased PRC
(161%) (Figure 1A–E). Changes in neurohumoral parameters with
aliskiren compared with placebo were similar in the MRA+ and
MRA2 subgroups; ANCOVA revealed no significant interaction
between MRA treatment and the effect of aliskiren for any neuro-
humoral parameter (Figure 3A). Although there were modest
differences in geometric mean reductions with aliskiren relative
to placebo in plasma NT-proBNP in the MRA+ subgroup relative
to the MRA2 subgroup, these may be attributed to differences in
baseline levels; 95% confidence intervals for the two subgroups
were completely overlapping and there was no significant inter-
action with MRA treatment status (Figure 3A).
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Table 2 Baseline neurohumoral and echocardiographic parameters (intent-to-treat population)














Plasma BNP, pg/mL [n ¼ 145] [n ¼ 154] [n ¼ 96] [n ¼ 102] [n ¼ 49] [n ¼ 52]
191.5 204.8 182.4 194.9 210.9 225.6




[n ¼ 141] [n ¼ 147] [n ¼ 93] [n ¼ 95] [n ¼ 48] [n ¼ 52]
1217 1387 1125 1244 1417 1690
(1002, 1479) (1168, 1647) (870, 1457) (998, 1551) (1055, 1903) (1275, 2240)
PRA, ng/mL/h [n ¼ 138] [n ¼ 146] [n ¼ 94] [n ¼ 96] [n ¼ 44] [n ¼ 50]
2.2 (1.7, 3.0) 1.8 (1.3, 2.4) 1.8 (1.2, 2.6) 1.4 (1.0, 2.1) 3.8 (2.3, 6.2) 2.8 (1.6, 4.8)
PRC, ng/L [n ¼ 134] [n ¼ 144] [n ¼ 93] [n ¼ 94] [n ¼ 41] [n ¼ 50]
30.8 25.2 25.6 21.0 46.5 35.7




[n ¼ 131] [n ¼ 145] [n ¼ 89] [n ¼ 97] [n ¼ 42] [n ¼ 48]
22.7 24.3 22.3 23.0 23.7 27.1
(19.0, 27.1) (20.8, 28.4) (18.0, 27.6) (18.9, 28.0) (16.9, 33.3) (20.7, 35.6)
Echocardiographic parameters
MR/LA, % [n ¼ 97] [n ¼ 101] [n ¼ 63] [n ¼ 66] [n ¼ 34] [n ¼ 35]
29.5 + 13.1 30.2 + 13.8 29.3 + 13.2 29.7 + 12.3 29.9 + 13.1 31.1 + 16.5
LVEF, %a [n ¼ 132] [n ¼ 139] [n ¼ 85] [n ¼ 95] [n ¼ 47] [n ¼ 44]
31.1 + 5.5 30.6 + 5.5 31.9 + 5.3 31.0 + 5.3 29.6 + 5.4 29.6 + 5.8
Blood pressure [n ¼ 146] [n ¼ 156] [n ¼ 97] [n ¼ 104] [n ¼ 49] [n ¼ 52]
msSBP, mmHg 127.6 + 16.4 130.2 + 18.3 128.8 + 16.5 133.0 + 17.2 125.1 + 16.1 124.7 + 19.2
msDBP, mmHg 76.4 + 8.4 78.1 + 10.4 77.1 + 8.4 78.5 + 10.0 75.1 + 8.5 77.1 + 11.3
Neurohumoral parameters are shown as geometric mean (95% confidence interval). Echocardiographic parameters are shown as mean+ SD. Data for patients with a value at
baseline are included.
BNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; MR/LA, mitral regurgitation to left atrial area ratio; msDBP,
mean sitting diastolic blood pressure; msSBP, mean sitting systolic blood pressure; NT-proBNP, N-terminal prohormone B-type natriuretic peptide; PRA, plasma renin activity;
PRC, plasma renin concentration.
aAs measured by core echocardiography laboratory.
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Figure 1 Changes from baseline in neurohumoral biomarkers according to mineralocorticoid receptor antagonist treatment status. (A)
B-type natriuretic peptide, (B) N-terminal prohormone B-type natriuretic peptide, (C) plasma renin activity, (D) plasma renin concentration,
and (E) urinary aldosterone. Data represent (A–E) percentage change from baseline in geometric mean (95% CI) in the overall population
and the subgroups of patients receiving (MRA+) or not receiving (MRA2) MRA treatment during the study. P values were calculated using
a two-way ANCOVA model with treatment, region, LVEF (.40 or ≤40%) and subgroup as factors, baseline as a covariate and treatment
by subgroup as an interaction. *P , 0.05 vs. placebo; **P , 0.005 vs. placebo; ***P , 0.0001 vs. placebo. ANCOVA, analysis of covariance;
CI, confidence interval; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist.
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Changes in echocardiographic
parameters
In the overall population, aliskiren 150 mg significantly improved
the mitral regurgitation to left atrial area ratio (MR/LA) compared
with placebo (25.2 vs. +0.6%, P ¼ 0.0003; Figure 2A); MRA treat-
ment status did not influence this effect of aliskiren (interaction
P ¼ 0.429; Figure 3B). Aliskiren treatment was associated with
small numerical increases in LVEF in the overall population and
in the MRA2 and MRA+ subgroups (Figure 2B), but these
changes were not significantly different from those seen with
placebo and there was no influence of MRA treatment status
(interaction P ¼ 0.409; Figure 3B).
Figure 2 Changes from baseline in echocardiography parameters and blood pressure according to MRA treatment status. (A) Mitral regur-
gitation to left atrial area ratio, (B) LVEF, and (C) blood pressure. Data (A–C) represent least-squares mean+ SEM in the overall population and
the subgroups of patients receiving (MRA+) or not receiving (MRA2) MRA treatment during the study. P values were calculated using a
two-way ANCOVA model with treatment, region, LVEF (.40 or ≤40%) and subgroup as factors, baseline as a covariate and treatment by
subgroup as an interaction. *P , 0.05 vs. placebo. ANCOVA, analysis of covariance; CI, confidence interval; LVEF, left ventricular ejection frac-
tion; MRA, mineralocorticoid receptor antagonist; msDBP, mean sitting diastolic blood pressure; msSBP, mean sitting systolic blood pressure;
SEM, standard error of the mean.
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Figure 3 Influence of MRA treatment on between-treatment comparisons (aliskiren vs. placebo) in (A) neurohumoral biomarkers and (B)
echocardiography parameters and blood pressure. Data are shown as ratio (aliskiren:placebo) of the geometric mean with associated 95% con-
fidence intervals (BNP, NT-proBNP, PRA, PRC, urinary aldosterone) or least-squares mean difference (aliskiren 2 placebo) with associated
95% confidence intervals (MR/LA, LVEF, blood pressure). P values were calculated using an ANCOVA model with treatment, region, LVEF
(.40 or ≤40%) and subgroup as factors, baseline as a covariate and treatment by subgroup as an interaction. ANCOVA, analysis of covariance;
BNP, B-type natriuretic peptide; CI, confidence interval; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist;
MR/LA, mitral regurgitation to left atrial area ratio; msDBP, mean sitting diastolic blood pressure; msSBP, mean sitting systolic blood pressure;
NT-proBNP, N-terminal prohormone B-type natriuretic peptide; PRA, plasma renin activity; PRC, plasma renin concentration.
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Changes in blood pressure
In the overall population, there was no significant between-
treatment difference in the change from baseline in msSBP or
msDBP (Figure 2C). In the MRA+ subgroup, aliskiren treatment
was associated with a significant decrease in msSBP (25.0 vs.
+0.8 mmHg, P , 0.05) from baseline compared with placebo
(Figure 2C). Analysis of covariance revealed no significant inter-
action between MRA treatment status and the effect of aliskiren
on msSBP (interaction P ¼ 0.105; Figure 3B) or msDBP (interaction
P ¼ 0.519; Figure 3B).
Safety and tolerability
Addition of aliskiren to standard HF treatment was generally well
tolerated. There were no significant differences between the aliski-
ren 150 mg and placebo treatment groups in the proportion of
patients who experienced at least one pre-defined adverse event
(renal dysfunction, symptomatic hypotension, or hyperkalaemia)
in the overall population (Table 3). There were more adverse
events with aliskiren compared with placebo in the MRA+ sub-
group than in the MRA2 one, although the numbers were small
and the increase was not statistically significant (Table 3). There
were also no notable differences between the aliskiren and
placebo groups in the proportion of patients with elevations
above pre-defined threshold in blood urea nitrogen, serum
creatinine, or serum potassium levels in either the MRA+ or the
MRA2 subgroups (Table 4).
Discussion
Recently, the value of adding another blocker of the effects of
angiotensin II to an ACE inhibitor in patients with HF has been
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Table 3 Safety and tolerability (intent-to-treat population)























11 (7.5) 17 (10.9) 0.329 7 (7.2) 8 (7.7) 0.898 4 (8.2) 9 (17.3) 0.170
Renal dysfunction 2 (1.4) 3 (1.9) 1.000 2 (2.1) 1 (1.0) 0.610 0 2 (3.8) 0.495
Symptomatic
hypotension
2 (1.4) 5 (3.2) 0.450 1 (1.0) 2 (1.9) 1.000 1 (2.0) 3 (5.8) 0.618
Hyperkalaemia 7 (4.8) 10 (6.4) 0.499 4 (4.1) 5 (4.8) 1.000 3 (6.1) 5 (9.6) 0.716
Table shows the number (%) of patients experiencing a pre-specified adverse event.
MRA, mineralocorticoid receptor antagonist.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Laboratory abnormalities (safety population)














[n ¼ 144] [n ¼ 156] [n ¼ 96] [n ¼ 104] [n ¼ 48] [n ¼ 52]
Serum potassium
,3.5 mmol/L 7 (4.9) 2 (1.3) 3 (3.1) 0 4 (8.3) 2 (3.8)
.5.5 mmol/L 12 (8.3) 13 (8.3) 7 (7.3) 6 (5.8) 5 (10.4) 7 (13.5)
≥6.0 mmol/L 6 (4.2) 3 (1.9) 4 (4.2) 2 (1.9) 2 (4.2) 1 (1.9)
Serum creatinine
.177 mmol/L 8 (5.6) 11 (7.1) 6 (6.3) 8 (7.7) 2 (4.2) 3 (5.8)
.265 mmol/L 3 (2.1) 0 3 (3.1) 0 0 0
BUN
.14.3 mmol/L 15 (10.4) 13 (8.3) 7 (7.3) 6 (5.8) 8 (16.7) 7 (13.5)
Table shows the number (%) of patients experiencing clinically notable changes in selected laboratory values while receiving treatment.
BUN, blood urea nitrogen; MRA, mineralocorticoid receptor antagonist.
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questioned while the indication for using an MRA has broadened
to potentially all patients with systolic HF. Specifically, the
interpretation of trials adding an ARB to an ACE inhibitor has
become controversial. The risk of death from cardiovascular
causes was not reduced in each of the two large placebo-
controlled trials in HF (although the risk of HF hospitalization
was in both).7,8 Secondly, the background ACE inhibitor and
dose did not match the evidence-based and regulatory standard
(i.e. enalapril at an average daily dose of 16.6 mg). Doubt about
the trials in HF has arisen because of the findings of two more
recent ARB ‘add-on’ trials: one in patients with acute myocardial
infarction and the other in patients with stable arterial
disease.9,10 In both, addition of an ARB to a full dose of an
evidence-based ACE inhibitor had no clinical benefit. Furthermore,
in all of the ARB ‘add-on’ trials, addition of an ARB to an ACE
inhibitor led to increased rates of hypotension, renal dysfunction,
and hyperkalaemia.4,5
More recently, an unequivocal benefit of an MRA has been
shown in patients with systolic HF and mild symptoms, consistent
with two other trials with an MRA in systolic HF with severe symp-
toms and systolic HF after acute myocardial infarction.2,3,11,12 MRA
were not commonly used at baseline in the aforementioned ARB
trials. Consequently, both the efficacy and safety questions about
adding a second renin–angiotensin blocker to an ACE inhibitor
have changed. In terms of efficacy, it is now important to know
whether the second renin–angiotensin blocker provides incre-
mental benefit not only on top of a full dose of an evidence-based
ACE inhibitor but also an MRA. This obviously raises a new safety
question about adding a second renin–angiotensin blocker not
only to an ACE inhibitor but also an MRA (and b-blocker).
The results of the current post-hoc analysis suggest that the effi-
cacy of aliskiren is maintained in patients receiving an MRA
(MRA+) at baseline, as evidenced by a similar reduction in
plasma BNP and NT-proBNP to those in the MRA2 subgroup.
Consistent with the results for the overall population, the
present analysis also showed that addition of aliskiren to standard
HF therapy led to reductions in urinary aldosterone and PRA levels
that were similar in both MRA subgroups. Most importantly, the
addition of aliskiren to the MRA+ subset was generally well toler-
ated even though these patients were receiving three RAAS inhibi-
tors (ACE inhibitor or ARB, MRA, and DRI), as well as a b-blocker
in most cases. Specifically, addition of aliskiren to standard HF
treatment with or without an MRA was not associated with an
increased incidence of pre-specified adverse events including
symptomatic hypotension, renal dysfunction, or hyperkalaemia.
Although there was a reduction in systolic blood pressure when
aliskiren was added to the MRA+ group, this reduction was not
significantly different from that observed in the MRA2 group. In
addition, there were no significant differences between the aliski-
ren and placebo groups in the proportion of patients with an
elevation of blood urea nitrogen, serum creatinine, or serum
potassium levels.
Although reductions in the levels of plasma BNP and NT-proBNP
have been associated with improved clinical outcomes in HF, these
are only surrogate outcomes.13 –15 Additionally, a post-hoc analysis
of one of the ARB ‘add-on trials’ showed that the benefit of cande-
sartan was consistent irrespective of background use of an MRA.16
Both surrogate outcomes and post-hoc analyses can be misleading.17
Fortunately, the safety and efficacy of adding aliskiren to convention-
al therapy in patients with HF is being addressed, appropriately, in an
ongoing, large-scale, mortality–morbidity trial (ATMOSPHERE) in
which the renin inhibitor is being compared directly with enalapril
10 mg twice daily and also given in addition to enalapril 10 mg
twice daily, i.e. a three-arm trial.6
In summary, this retrospective analysis of the ALOFT study
showed that the natriuretic peptide lowering effect of aliskiren
was consistent in patients not treated and treated with an MRA
and that there was no excess of renal dysfunction when aliskiren
was added to an ACE inhibitor (or ARB) and MRA, as well
as a b-blocker in most cases. However, only the results of a
well-powered, prospective, randomized trial will answer the ques-
tion as to whether the addition of a DRI to an ACE inhibitor (or
ARB) and a b-blocker with or without an MRA will be safe and
effective in patients with HF.
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